The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | Neoadjuvant PD-1 & PD-L1 blockade with chemotherapy for stage III NSCLC
In this latest episode of the VJOncoAlert Journal Club, Biagio Ricciuti, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses results from a multicenter cohort study evaluating the efficacy of neoadjuvant PD-1 or PD-L1 blockade combined with chemotherapy in enhancing surgical outcomes and pathological responses in patients with T4 and/or N2-N3 stage III non-small cell lung cancer (NSCLC).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
